Alzheimer's Association International Conference

Avanir Pharmaceuticals releases data on PBA drug

Avanir Pharmaceuticals has announced data on pseudobulbar affect, a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA®, the only FDA-approved product for the treatment of PBA. Results will be presented at the Alzheimer's Association International Conference in Copenhagen, Denmark, which runs July 12 through 17.

Sunlight treatment could help nighttime wandering in people with Alzheimer's, study suggests

By

The tendency of Alzheimer's patients to wander at night could be tied to the quantity of daylight they're exposed to, new research finds. As a result, experts say that "light therapy" could be helpful in treating this behavior.

Study: Experimental Alzheimer's drug stabilizes symptoms for up to three years

Treatment with an experimental intravenous Alzheimer's medication stabilized dementia symptoms for a sustained period in trial participants, new research reveals. Investigators called it a "first" in Alzheimer's research.

Familial versions of Alzheimer's could be detected two decades before symptoms start, research finds

Inheritable types of Alzheimer's disease could be detectable up to 20 years before the onset of memory and cognition problems, new research suggests.